Mechanism and therapeutic potential of cyclophilin inhibitors for prevention of mitochondrial myopathy progression
Prof. Håkan Westerblad from the Karolinska Intitutet, Stockholm, Sweden will give a presentation about “Mechanism and therapeutic potential of cyclophilin inhibitors for prevention of mitochondrial myopathy progression” during the next 9th World Congress on Targeting Mitochondria, which will be held at Steigenberger Hotel, Berlin on October 23-25, 2018.
According to Prof. Håkan Westerblad: "Mice with skeletal muscle-specific disruption of the mitochondrial transcription factor A (Tfam), Tfam knock-out (KO) mice, develop a lethal mitochondrial myopathy. We have identified excessive mitochondrial Ca2+ uptake as a likely trigger of muscle dysfunction in Tfam KO mice. The expression of the mitochondrial protein PPIF (also called cyclophilin D) is increased in muscles of TFam KO mice as well as in patients with mitochondrial myopathy. The cyclophilin inhibitors cyclosporine A and NV556 decrease mitochondrial Ca2+ uptake in Tfam KO muscles and prolong the lifespan of Tfam KO mice.".
For more information about Targeting Mitochondria 2018, please visit www.targeting-mitochondria.com
